Abstract: A camera module is provided. The camera module includes a lens assembly, a blade set disposed on an upper surface of the lens assembly and adjusting a diameter of a lens incident hole, a rotational drive part connected to the blade set and controlling movement of blades through a rotary motion, a blade connecting part connected to one side of the rotational drive part and rotating the rotational drive part, a linear moving part connected to the blade connecting part and accommodating a blade drive magnet on its outer side and a blade drive coil disposed opposite to the blade drive magnet, wherein in accordance with a current applied to the blade drive coil, the camera module adjusts a diameter of the lens incident hole by linearly moving the linear moving part within a blade drive aperture, which is disposed on a first side of a side frame.

Abstract: A camera module includes a lens assembly, at least two blades that are on a top surface of the lens assembly and define a lens light entrance hole, a moving drive magnet, a fixed drive magnet, a blade controller that is coupled to the moving drive magnet and to the at least two blades, where the blade controller is configured to control a movement of the at least two blades, a lens assembly body, where the lens assembly and the fixed drive magnet are on the lens assembly body, and a frame that at least partially surrounds the lens assembly body and includes a coil that faces the moving drive magnet, where the blade controller is configured to adjust a diameter of the lens light entrance hole by controlling the moving drive magnet to move based on a current applied to the coil.

Abstract: A stator assembly is provided and includes a stator element and a radial height adjustment mechanism. The stator assembly includes an inboard portion which establishes a primary clearance with rotor elements and exhibits a measurable parameter corresponding to the primary clearance and an outboard portion integrally formed with the inboard portion. The radial height adjustment mechanism is coupled with the outboard portion and configured to be operable, based on the measurable parameter, to adjust a radial height of the stator element and in turn to adjust the primary clearance.

Abstract: A stator cluster is provided and includes inner and outer stator walls, stator vanes radially interposed between the inner and outer stator walls and a stanchion body connected to and extending radially outwardly from the outer stator wall. At least the stator vanes, the outer stator wall and the stanchion body are formed to define internal paths.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: A stator cluster is provided and includes inner and outer stator walls, stator vanes radially interposed between the inner and outer stator walls and a stanchion body connected to and extending radially outwardly from the outer stator wall. At least the stator vanes, the outer stator wall and the stanchion body are formed to define internal paths.

Abstract: Provided herein are USP28 inhibitors, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment and/or diagnosis.

Abstract: A separator device (100) includes a separation chamber (107) defined at its lower end by a fluidization fluid panel (111). The separation chamber (107) receives incoming slurry (113) via a slurry inlet (102). The separator device may be characterized in that means (122) for supplying pre-sheared aerated fluidization fluid is provided above the fluidization fluid panel (111). The means (122) for supplying pre-sheared aerated fluidization fluid includes a novel sparger (119) comprising a flexible perforated membrane which is configured to supplementally shear the pre-sheared aerated fluidization fluid and uniformly distribute microbubbles (129) throughout the separation chamber (107).

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: A feedwell assembly (1) having a feedwell (3) and feed dilution apparatus (27) is characterised in that the feed dilution apparatus (27) includes a centrifugal impeller (16) arranged within a pump housing (9). The pump housing is arranged below a weir box (12) having an upper opening and a spill lip (12b). The spill lip (12b) is arranged at an upper periphery of the weir box (12). The spill lip (12b) is configured to be arranged below an air-liquid interface (20) during operation such that there is a depth of submergence (26) between the spill lip (12b) and the air-liquid interface (20).

Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: Disclosed is an apparatus for continuous spinning of coagulative polymeric microfibers comprising an outer microcatheter, an inner microcatheter having a smaller diameter than the outer microcatheter and inserted inside the outer microcatheter, a double lumen part in which the outer microcatheter and the inner microcatheter are coaxially superimposed with a radially spaced interstitial space, and a single lumen part formed by the outer microcatheter from an end of the inner microcatheter to an end of the outer microcatheter. A core fluid supplied through an interior of the inner microcatheter comprises a coagulative polymeric fluid, and a sheath fluid supplied through the interstitial space comprises a fluid including saline, wherein the core fluid and the sheath fluid may be configured to flow coaxially in the single lumen part to generate and discharge a coagulative polymeric microfiber.

Abstract: Disclosed are a method for performing network fault management in a cloud environment and a network fault management system. A method for performing network fault management in a cloud environment according to another exemplary embodiment of the present invention includes steps of measuring, by testing tools, the performance of a target server and transmitting a measurement result to a fault management unit, determining, by the fault management unit, a threshold and a policy for a target host based on the transmitted measurement result, generating, by the fault management unit, templated information including the determined threshold and policy, transmitting, by the fault management unit, the templated information to monitoring tools, and setting, by the monitoring tools, a monitoring policy of the target host based on the transmitted information.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

Abstract: The present invention relates to a three-dimensional structure electrode, a method for manufacturing same, and an electrochemical element including the electrode. The present invention is characterized by comprising: (a) an upper conductive layer and a lower conductive layer which have a structure constituting an assembly within which a conductive material and a porous nonwoven fabric including a plurality of polymeric fibers are three-dimensionally connected in an irregular and continuous manner, thereby forming a mutually connected porous structure; and (b) an active material layer forming the same assembly structure as the conductive layers and forming a three-dimensionally filled structure in which electrode active material particles are uniformly filled inside the mutually connected porous structure formed in the assembly structure, wherein the active material layer is formed between the upper conductive layer and the lower conductive layer.

Abstract: Disclosed is an apparatus for continuous spinning of coagulative polymeric microfibers comprising an outer microcatheter, an inner microcatheter having a smaller diameter than the outer microcatheter and inserted inside the outer microcatheter, a double lumen part in which the outer microcatheter and the inner microcatheter are coaxially superimposed with a radially spaced interstitial space, and a single lumen part formed by the outer microcatheter from an end of the inner microcatheter to an end of the outer microcatheter. A core fluid supplied through an interior of the inner microcatheter comprises a coagulative polymeric fluid, and a sheath fluid supplied through the interstitial space comprises a fluid including saline, wherein the core fluid and the sheath fluid may be configured to flow coaxially in the single lumen part to generate and discharge a coagulative polymeric microfiber.